乐观
$24.86
情景价格
$21.230
-1.119 (-5.27%)收盘时
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
SI-BONE Inc is a good buy right now due to its current price of $21.48, a strong RSI of 78.24 indicating momentum, and a gross margin of 79.54% which showcases effective cost management. The company has also received FDA clearance for its Onyx system, which is expected to drive future revenue growth. However, the main risk is the negative earnings per share (EPS) of -0.09 projected for the next quarter, indicating ongoing losses.
UBS
$25
2026-08-04
UBS
2026-08-04
目标价
$25
TD Cowen
$20
2026-08-04
TD Cowen
2026-08-04
目标价
$20
Truist
$23
2026-08-04
Truist
2026-08-04
目标价
$23
UBS
$24
2026-07-28
UBS
2026-07-28
目标价
$24
Truist
$21
2026-07-16
Truist
2026-07-16
目标价
$21
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

SI-BONE Receives FDA Clearance for Onyx System

SI-BONE (SIBN) Q2 2026 Earnings Call Insights

SI-BONE Reports Narrowed Net Loss and Revenue Growth in Q2 2026

SI-BONE Q2 Earnings Exceed Expectations

ViCentra Appoints New CFO and Independent Board Member
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
SI-BONE Inc is a good buy right now due to its current price of $21.48, a strong RSI of 78.24 indicating momentum, and a gross margin of 79.54% which showcases effective cost management. The company has also received FDA clearance for its Onyx system, which is expected to drive future revenue growth. However, the main risk is the negative earnings per share (EPS) of -0.09 projected for the next quarter, indicating ongoing losses.
4 analysts cover SIBN: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.17.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。